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Abstract
Background: The aim of study was to investigate predictors of long term use of psychiatric services of patients
with recent-onset schizophrenia.
Methods: A cohort of 50 clinically stable patients with recent-onset schizophrenia was included in a randomized
controlled trial comparing early integrated treatment with treatment as usual. Recent onset was defined as
emergence of psychotic symptoms for the first time during the preceding 2 years. The follow up period was
from the date of randomization and until 12 years after termination of treatment trial, 14 years forward.
Results: Score on Brief psychiatric rating scale both at baseline and after 2 years of treatment, suicide attempts
during 2 years of treatment and being an inpatient during 2 years of treatment were significant predictors of long
term use of services.
Conclusion: High score on Brief psychiatric rating scale, suicide attempts and being admitted as inpatient early in
the course of schizophrenia are possible predictors of long term use of services.
Trial registration: ClinicalTrials.gov NCT00184509. Registered 15 September 2005.
Keywords: Schizophrenia, Hospitalizations, Mental health service use
Background
Schizophrenia has been described as a chronic, relapsing
disease, although with a heterogeneous course and out-
come [1]. It manifests itself as a mixture of positive,
negative, cognitive and mood symptoms, with general
decay in function and social disability [2]. Schizophrenia
is associated with increased suicide-rate [3] and reduced
longevity [4]. Onset of psychotic symptoms usually oc-
curs during adolescence or early adulthood.
The so called “critical period hypothesis” claims that
in schizophrenia deterioration occurs rapidly during a
period of few years following psychotic debut [5].
Subsequently the disease reaches a “plateau”, deterior-
ation slows down or halts, and the disease reaches a
level of morbidity which remains relatively stable [6].
Interventions applied at the early stages of the critical
period might have the potential of preventing or dimin-
ishing the progressive deterioration and thereby improv-
ing long term prognosis [7].
Re-hospitalization following relapse is one of the cost-
liest interventions in schizophrenia and increases the
burden associated with psychotic illness [8–10]. The pre-
diction of prognosis early in the course of illness can
help developing optimal treatment strategies throughout
the duration of disease course. Identifying risk factors
for the use of in- and outpatient psychiatric services may
have implications on clinical decisions, policy for patient
care, program development, and service planning. Early
identification of poor responders would allow timely ad-
justments to management programs and modifiable pre-
dictors may present specific treatment targets.
The aim of the study was to investigate possible base-
line and 2 year predictors of long term use of psychiatric
services of patients with recent-onset schizophrenia.
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A cohort of 50 patients with recent-onset non-affective
psychosis were included in a randomized controlled trial
comparing early integrated treatment (IT) with treat-
ment as usual (TAU). Recent onset was defined as emer-
gence of psychotic symptoms for the first time during
the preceding 2 years. TAU comprised optimal pharma-
cotherapy and case management, while IT also included
cognitive-behavioural family treatment, which incorpo-
rated skills training, cognitive-behavioural strategies for
residual psychotic and non-psychotic problems and
home-based crisis management. Participants were ran-
domly allocated using a sequence of sealed pre-
numbered envelopes with group assignments according
to random numbers provided by the international
Optimal Treatment Project administration. Gender was
stratified in blocks of varying size (between 8 and 12
and with a ratio of 3:2 of IT to TAU) ensuring that a
majority of the patients received the experimental treat-
ment. Prior to randomization written informed consent
was obtained. The intervention program and the results
of the trial are reported in detail elsewhere [11–14], see
also the Additional file 1.
The research was carried out in compliance with the
Helsinki Declaration and the study was approved by The
Regional Committee for Medical and Health Research
Ethics in Central-Norway.
Recruitment
The patients were included from 1992 to 1997. The
catchment area was a county in Mid-Norway with a
population of about 250.000 inhabitants. At the time
of inclusions, no effort was made to reduce the delay
in seeking treatment in this region, but efforts were
made to get referrals of all patients with recent onset
psychotic disorder from psychiatric inpatient units,
outpatient clinics, and general practitioners in the
area. Patients who were clinically stable and were ex-
pected to reside in the county for at least 1 year after
inclusion were asked to participate in the study. Pa-
tients with substance use disorders or mental retard-
ation were excluded.
The focus of the present study was to identify predic-
tors of long term use of services for patients with a
recent-onset psychosis.
Follow up
The follow up period was from the date of randomization
until 12 years after termination of treatment trial, 14 years
forward. The cohort was divided into two groups based
on the number of days as psychiatric inpatients during
12 years after termination of the treatment trial. This was
based on inspection of the data showing a marked divid-
ing line in participants’ inpatient days around 100 days.
Measures
Data on duration and number of psychiatric hospital ad-
missions was extracted from the official Patient Admin-
istrative System, a standard system for clinical data in
the health trust. Data was verified trough scrutiny and
cross-checking of medical records.
Information used in this study was registered at base-
line and 2 years after inclusion into the original study.
Baseline factors: Age, gender and residence. Diagnosis
according to DSM-IV and overall function assessed
using Global assessment of function (GAF) [15]. Psycho-
pathology was assessed using Brief psychiatric rating
scale (BPRS) [16] and Target symptoms rating scale
(TSRS) [17]. Incidences and duration of hospitalisations
before study entry was also recorded.
Factors after the 2 year treatment trial
Overall function assessed using Global assessment of
function (GAF) [15] and psychopathology assessed using
Brief psychiatric rating scale (BPRS) [16] and Target
symptoms rating scale (TSRS) [17] at the end of the
trial. Suicide attempts defined as attempts with an
intention to die and adherence to psychosocial treatment
and adherence to treatment with psychotropics were
also registered during the 2 year trial. Incidences and
duration of hospitalisations, incidences and duration of
in- and outpatient coercion and contact with community
or specialist health services were also registered during
the 2 year treatment trial. Integrated treatment or treat-
ment as usual according to the randomized controlled
study the 2 year treatment trial. In Table 1 possible pre-
dictors of long term use of services at baseline and ob-
servations during 2 years of treatment are referred.
Operational variables
During the 2 year treatment trial
“Psychotic relapse” was defined as a two-point increase
and a score of six or seven on the TSRS (0–7) [17] and a
score of six or seven on one of the key psychotic symp-
tom items on the BPRS (1–7) OR a two-point increase
and a score of four or five on the TSRS following a
period of remission.
A score of five or more on “hallucinations” or “unusual
thoughts” items on BPRS for more than six consecutive
months was defined as having “persistent psychotic symp-
toms” [11]. Positive symptoms sub-score on BPRS was de-
fined as sum score of the items “unusual thought
content”, “suspiciousness”, “grandiosity”, “hallucinations”,
“conceptual disorganization” and “bizarre behaviour”.
Negative symptoms sub-score was defined as sum score of
the items “blunted affect”, “emotional withdrawal”, “motor
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retardation”, “self-neglect” and “disorientation” [18]. Com-
pliance with psychosocial treatment was considered
“good” if patients attended at least one session per month
during the treatment period. Patients with less than
1 month or fewer than four single weeks without medica-
tion were rated as adherent with medication. Patients re-
ceiving depot injections of antipsychotics at any time were
recorded as depot users [11].
During the 12 year follow-up
“Frequent users” were defined as patients with 100 or
more hospital days during the follow up period.
“Non-frequent users” were defined as a patient with
less than 100 days as psychiatric inpatients during the
follow up period.
A subgroup of “frequent users”, with more than 500
inpatient days during the follow up period was defined
as “extensive users” for further exploration.
Missing data
Twenty four months registration on the BPRS was miss-
ing for five patients. In these cases we used last available
registration. Three patients had last registration at
22 months, one at 20 months and one at 6 months.
Analysis
Statistical methods
First, bivariate relationships between frequent users and
the independent variables were explored. Second, pos-
sible predictors of becoming frequent users were ana-
lysed using logistic regression.
For logistic regression, general rules of thumb state that
there should be at least five to ten times as many cases in
the smallest group as the number of predictors [19, 20].
Hence, we included four predictors simultaneously.
Selection of variables
Selecting factors for inclusion in a multivariable model
based on statistical significance in a bivariate analysis is
not optimal as it may exclude possible confounders that
impacts outcome when included in the model [21]. We
therefore based our selection of variables on previous re-
search on prognostic factors in schizophrenia and on
what we considered of clinical relevance.
Age at onset and male gender are known to affect
prognosis and the extent of use of services of patients
with schizophrenia [22, 23], BPRS has been shown to be
an applicable tool to predict length of hospital stay [24]
and previous admissions have been found to predict fu-
ture admissions [25]. We selected age, gender and treat-
ment regime (Integrated treatment or treatment as
usual) to be adjusted for in the logistic regression ana-
lysis of potential predictors of long term use of services.
There was a striking difference between the groups in
suicide attempts during the 2 year treatment trial (zero
patients attempted suicide in the non-frequent users
group and five in the frequent users group) and suicidal
behaviour has been found to be a predictor of psychi-
atric admissions [26].
Statistical analyses
Positive symptoms after 2 years were influenced by an
extreme score in the non-frequent group and the
Table 1 Possible predictors of long term use of services at






Urban / Rural X
ASSESSMENTS
Diagnosis X
Global Assessment of functioning (GAF) X X
Brief Psychiatric Rating Scale (BPRS) X X
Psychotic relapse:
A 2-point increase and a score of 6 or 7 on the
Target Symptoms Rating Scale (TSRS) and a
score of 6 or 7 on one of the key psychotic
items on the BPRS OR a 2-point increase and a




A score of 5 or more on “hallucinations” or










Days hospitalized Year preceding
study entry
X
No. of hospitalizations - X
Involuntary admitted X
Days involuntary admitted X
Outpatient coercion X
Days outpatient coercion X
Treatment
Integrated treatment X
Good adherence with oral or depot
antipsychotics
Less than 1 month or fewer than 4 single weeks
without medication
X
Good adherence with psychosocial treatment
Attended at least one session per month during
the treatment period
X
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variance of days hospitalized and number of hospitaliza-
tions during the 2 year treatment period, days involun-
tary hospitalized and days involuntary outpatient
coercion during 2 year treatment period in the two
groups, were skewed and therefore we used the non-
parametric Mann-Whitney test for these variables in the
bivariate analysis. Proportions were compared using the
unconditional z-pooled test as recommended by Lyder-
sen, Langaas and Bakke (2012). This test preserves the
type I error and has substantially higher statistical power
than Fisher's exact test in small samples.
Potential predictors for frequent users were analysed
using logistic regression, with one potential predictor at
a time, unadjusted, and adjusted for age, sex and treat-
ment group (IT or TAU). Hospital days during 12 years
after end of treatment were not normally distributed. As
suggested by Tabatchnick & Fidell [27], we attempted
the log transformation (after adding 1 to avoid trying to
take the logarithm of zero) and the square root trans-
formation. Only the square root gave acceptable ap-
proximation to the normal distribution, judged by visual
inspection of QQ plots.
As secondary analyses we carried out linear regression
analyses with square root transformed days in hospital
during 12 years after treatment as dependent variable.
Statistical analyses were done in SPSS 20 except the
unconditional z-pooled test which was done in the soft-
ware http://www4.stat.ncsu.edu/~boos/exact/.
Results
Complete 12 year follow-up data on use of services for
45 of the 50 patients were accessible from hospital re-
cords. Five patients had migrated from the region. One
patient, randomized into the TAU group, died 4 years
and 9 months into the follow-up period. Data from the
deceased participant was included. Among the 45 pa-
tients, 21 were frequent users and 24 non-frequent
users, see Table 2.
Frequent users had a mean (SD) of 710 (656) days as
inpatients and a median of 423 (Min 104–Max 2521),
while non-frequent users had a mean (SD) of 13 (29)
days and a median of zero (Min 0–Max 97), p < 0.001.
During the 12 year follow-up period, 17 patients had no
hospitalizations and 10 patients were hospitalized for
more than 500 days.
Bivariate analysis
In the bivariate analysis, gender, GAF, total score BPRS
and score on BPRS positive factors at baseline were sig-
nificantly associated with being a frequent user.
After the 2 years treatment trial were GAF, total score
BPRS, psychotic relapse, suicide attempt, number of
hospitalizations, days as inpatient, involuntary admitted,
days involuntary admitted, outpatient coercion, days
with outpatient coercion and not having good adherence
with oral or depot antipsychotics significantly associated
with being a frequent user. See Tables 3 and 4.
Regression analysis
Female gender and high score on BPRS and low score
on GAF were significant baseline predictors of becoming
Table 2 Use of inpatient days through 12 years divided on






usual N = 17
Non-frequent
users N = 21
No admittances 13 4




100 to 500 days 6 8
More than 500 days 6 4














Age. Mean (SD) 24.5 (4.5) 23.9 (4.0) 25.1 (4.9) .36 a)
Female, No. (%) 18 (40) 13 (54) 5 (24) .045*c)
Urban No. (%) 27 (60) 15 (63) 12 (57) .76 c)
Diagnosis DSM-IV
No. (%)
Schizophrenia 37 (82) 20 (83) 17 (81) -
- Schizo-affective 6 (13) 3 (13) 3 (14) -








BPRS baseline, 24 items.
Mean (SD)
39.7 (7.6) 42.1 (7.5) 36.9 (6.9) .020*a)
- Neg. sympt. Mean (SD) 9.4 (3.4) 9.7 (3.5) 9.1 (3.2) .55 a)
- Pos. sympt. Median, (mean) 9 (9.6) 10.5
(10.7)
7 (8.3) .021*b)
Min Max Min Max Min Max




39 (87) 20 (83) 19 (90) .53 c)
Days hospitalized year









BPRS Brief Psychiatric Rating Scale
GAF Global assessment of function
SD Standard deviation
a) T-test, b) Mann-Whitney test c) Exact unconditional z-pooled test
*Statistically significant
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a frequent user in the logistic regression analysis, see
Table 5, both unadjusted and adjusted for age, gender
and treatment group.
After the 2 years treatment trial, score on BPRS, score
on GAF, being admitted to hospital and having a psych-
otic relapse were all significant predictors for being a
frequent user.
As an alternative, the analyses were carried out in lin-
ear regression. In linear regression, the dependent vari-
able number of days was square root transformed to
make the residuals approximately normally distributed.
Results (data no shown) were similar to those in logistic
regression.
In an attempt to identify patients in high risk of
long-term frequent or extensive use of services we
constructed a “high risk group” from categorical vari-
ables showing the most profound difference between
groups during the 2 year treatment trial; suicide at-
tempt, outpatient coercion and being hospitalised. 22
patients, 75% of frequent users and all of extensive
users, fulfilled the inclusion criteria for the “high risk
group”. See Table 6.
Table 4 Bivariate analysis of predictors for long time services, 2 years after inclusion
Total (n = 45) Frequent users (n = 24) Non-frequent users (n = 21) P-value
Assessments
GAF 24 months. Mean (SD) 55.2 (17.3) 49.1 (13.8) 62.1 (18.5) .010* a)
BPRS 24 items, 2 years. Mean (SD) 36.4 (9.2) 39.8 (7.5) 32.5 (9.7) .007* a)
-Neg. symptoms Mean (SD) 7.7 (3.7) 8.0 (3.7) 7.4 (3.7) .63 a)
-Pos. symptoms Median (mean) 8 (9.8) 9 (10.6) 6 (8.8) .009* b)
Min Max Min Max Min Max
6 29 6 18 6 29
Psychotic relapse 2 years. No. (%) 23 (51) 17 (71) 6 (29) .008* c)
Persistent psychotic sxs 0–24 months. No. (%) 11 (24) 8 (33) 3 (14) .14 c)
Attempted suicide 2 years. No (%) 5 (11) 5 (21) 0 (0) .032* c)
Use of services
Hospitalized 0–24 months. No (%) 20 (44) 16 (67) 4 (19) .001* c)
No. of hospitalizations 0–24 months. Median (mean) 0 (1.2) 1 (2.1) 0 (0.2) .001* b)
Min Max Min Max Min Max
0 16 0 16 0 2
Days inpatient 0–24 months. Median (mean) 0 (55.8) 25.5 (92.2) 0 (14.2) .001* b)
Min Max Min Max Min Max
0 295 0 295 0 235
Involuntary admitted 0–24 months. No. (%) 18 (40) 13 (54) 5 (24) .045* c)
Days involuntary admitted 0–24 months. Median (mean) 0 (41.9) 10.5 (63.5) 0 (17.2) .025* b)
Min Max Min Max Min Max
0 294 0 294 0 236
Outpatient coercion 0–24 months. No. (%) 6 (13) 6 (25) 0 (0) .015* c)
Days outpatient coercion 0–24 months. Median (mean) 0 (47.0) 0 (88.1) 0 (0.00) .015* b)
Min Max Min Max Min Max
0 560 0 560 0 0
Treatment
Integrated treatment No. (%) 28 (62) 12 (50) 16 (76) .078 c)
Good adherence with oral or depot antipsychotics. No. (%) 32 (71) 14 (58) 18 (86) .049* c)
Good adherence with psychosocial treatment No. (%) 41 (91) 21 (87.5) 20 (95) .47 c)
GAF Global assessment of function
BPRS Brief Psychiatric Rating Scale
a) T-test, b) Mann-Whitney test c) Exact unconditional z-pooled test
*Statistically significant
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Discussion
This is one of few long-term prospective studies of re-
cent onset psychosis and the main findings are that both
at baseline and at 2 years there was a remarkable overlap
in the predictive value of the psychopathological indices,
i.e., this kind of stability indicate that in order to gain
knowledge about long term course and hospitalization
costs, it may be sufficient to assess risk factors at illness
onset and initial treatment response.
During the 2 year treatment trial, poorer functioning,
relapses and psychiatric hospitalizations, poor compli-
ance with medication and suicide attempts predict
higher use of inpatient services in the long-term follow-
up. These also suggest that the initial treatment response
is important, as is insight.
Total score on BPRS both at baseline and at 2 years
were significant predictors of use of services 12 years
after end of trial. Earlier research has shown predictive
validity of BPRS score on length of hospital stay and
its applicability in identification of patients who re-
quired non-acute extended hospital care [18, 28, 29].
Our results suggest that BPRS can be used to identify
patients early in the course of schizophrenia who are
likely to be frequent users of inpatient services in the
future. This can be helpful in planning future inter-
ventions for this group of patients in order to improve
prognosis and minimize the need of psychiatric ser-
vices in the future.
Several factors the two first years that usually are con-
sidered to have a negative influence on the course of
schizophrenia as reduced function (GAF), psychotic
relapses, being admitted, being under coercion and
reduced compliance with treatment were associated
with being a frequent user in the next 12 years in bi-
variate analyses.
Suicide attempts during intervention period showed a
significant relation to use of services in the uncondi-
tional z-pooled test indicating a significant association.
In the Northern Finland Birth Cohort [30] both suicide
attempts and high level of symptoms at baseline pre-
dicted poor outcome. Up to 5% of patients with schizo-
phrenia will commit suicide [31] and the estimated rate
of suicide attempts are close to 10 times that rate [32].
In our sample one patient died of complications to a sui-
cide attempt and five patients attempted suicide. This
relatively low rate of suicidality compared to other stud-
ies, may be due to the inclusion criteria excluding
Table 5 Logistic regression analysis of baseline and 2 year predictors for long time use of services
OR unadjusted OR adjusted for age, gender and treatment group
Estimate (CI) P-value Estimate (CI) P-value
Predictors baseline
Age (years) 0.94 (0.82 to 1.07) 0.36 0.962 (0.833 to 1.11) 0.599
Male gender 0.26 (0.073 to 0.96) 0.043a 0.25 (0.064 to 0.970) 0.045a
BPRS baseline 1.11 (1.01 to 1.21) 0.028a 1.10 (0.997–1.121) 0.057
Days as inpatient 1 year preceding baseline 0.998 (0.992 to 1.004) 0.44 0.998 (0.992 to 1.004) 0.496
Negative symptoms 0.889 (0.727–1.088) 0.253 0.855 (0.677–1.080) 0.19
GAF baseline 0.913 (0.854–0.982) 0.013a 0.92 (0.857–0.989) 0.024a
Predictors 2 years
BPRS 2 years 1.10 (1.02 to 1.19) 0.013a 1.1 (1.006 to 1.20) 0.036a
Days as inpatient 2 years after baseline 1.013 (1.002–1.024) 0.023a 1.010 (0.999 to 1.022) 0,082
Integrated treatment or Treatment as usual 0.31 (0.087 to 1.13) 0.076 0.29 (0.073 to 1.14) 0.077
Admitted to hospital the first 2 years after baseline 8.5 (2.137–33.814) 0.002a 10.411 (1.956–55.399) 0.006a
Negative symptoms 0.935 (0.773–1.129) 0.484 0.845 (0.673–1.060) 0.146
GAF 0.950 (0.912–0.991) 0.017a 0.949 (0.907–0.993) 0.023a
Compliance medication 4.286 (0.988–18.586) 0.052 0.097 (0.015–0.607) 0.013a
Absence of psychotic relapse 0.165 (0.045–0.600) 0.006a 0.135 (0.029–0.632) 0.010a
BPRS Brief Psychiatric Rating Scale
GAF Global Assessment of Function
asignificant results
Table 6 Prediction of being a frequent user of inpatient days
during 12 years. Divided in in a high risk group defined as
being admitted or having a suicide attempt or outpatient
coercion the preceding 2 years of treatment
User group
Frequent user Non frequent user
High risk group 18 4
Low risk group 6 17
Sensitivity 75%, Specificity 81%, Positive predictive value 82%, Negative
predictive value 74%
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patients with substance abuse; a known risk factor for
suicide in schizophrenia [33].
Male gender was a significant predictor in the logistic
regression analysis for being a non-frequent user, both
unadjusted and when adjusted for age and treatment al-
ternatives. Male gender is a known risk factor of suicid-
ality [34], but all of the patients in the present study
who attempted or committed suicide were female. Also
in the literature males have consistently been found to
have a less favourable course of illness than females, [23,
35, 36], but our results appear to show the opposite ten-
dency regarding use of services. The gender differences
in suicide attempts and use of services might be due to
the exclusion of patients with substance abuse as in
schizophrenia this is more prevalent among males [37].
A considerable number of patients, 17 (38%), were not
hospitalized during the follow up period. Two other
studies with 10 years follow-up of early psychosis
showed that around 40% of the patients in the OPUS
study had recovery or symptom remission at 10 years
follow-up [38] and 46% in the ÆSOP-study had been
symptom free for 2 years [39]. This is in accordance
to previous research on long term outcome in schizo-
phrenia showing good outcome in up to 50% of pa-
tients with schizophrenia [40]. In a previous report
we have described that ten patients were extensive
users and had more than 500 inpatient days and were
responsible for 76% of all inpatient days during the
follow up period (14).
By categorizing patients into a high risk group defined
by being admitted or having a suicide attempt or at out-
patient coercion in the first 2 years in the treatment
study, a positive predictive value of 82% for being a fre-
quent user were found. This can be a useful tool when
planning future treatment strategies.
Limitations
A sample size of 45 limited the number of variables in-
cluded in the logistic regression analysis. The selection
of variables included was based on previous research on
prognostic factors in schizophrenia and on what we con-
sidered of clinical significance in the actual sample. Only
a large sample size would have been sufficient to test all
possible variables from the bivariate analysis. Other vari-
ables chosen by other assumptions might have given dif-
ferent results. Dichotomizing a continuous outcome
variable may have reduced the statistical power to detect
a relation between the independent variables and out-
come [41].
Use of inpatient services may not be an optimal meas-
ure of outcome in schizophrenia and other aspects of re-
covery should also be considered. Clinically unstable
patients and patients with substance abuse were not
included in the study and this might reduce the
generalizability of the study. The long observation
period, the possibility to get complete data from 90% of
the participants and strict selection of appropriate statis-
tical measures are major strengths in the study.
Conclusion
Being admitted in the start of treatment, scores on BPRS
and history of suicide attempts appear to be applicable
measures in predicting the extent of future use of in-
patient services in schizophrenia.
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